Therapy News and Research

RSS

High levels of satiety hormone leptin contribute to cardiovascular disease in obese individuals

While high levels of the satiety hormone leptin don't help obese individuals lose weight, they do appear to directly contribute to their cardiovascular disease, researchers report.

8 Oct 2015

Head injury patients do not benefit from brain cooling therapy

Head injury patients do not benefit from a therapy that involves cooling their bodies to reduce brain swelling, research has found.

8 Oct 2015

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.

7 Oct 2015

Interim data from long-term extension Tecfidera® (dimethyl fumarate) study

Biogen (NASDAQ: BIIB) will, this week, present data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, demonstrating the efficacy and safety of TECFIDERA® (dimethyl fumarate) across a broad range of people with relapsing-remitting multiple sclerosis (RRMS).

7 Oct 2015

Cell Therapy Catapult launches Cell History File

The Cell Therapy Catapult, the organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announces the availability of the Cell History File (CHF) template document. The Cell History File template has been developed in conjunction with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), the Human Tissue Authority (HTA) and other cell therapy developers and manufacturers from academia and industry.

7 Oct 2015

Texas Center for Proton Therapy lures top proton talent as Dallas center nears opening

Texas Center for Proton Therapy has announced the hiring of three dedicated radiation oncologists with experience in radiation oncology and proton beam cancer treatment, completing the center’s key medical staff.

7 Oct 2015

2-year advanced melanoma survival benefit with dabrafenib, trametinib combination

Updated results from the COMBI-v trial show significantly improved overall and progression-free survival with first-line dabrafenib plus trametinib compared with vemurafenib in patients with advanced melanoma.

7 Oct 2015

Everolimus, 177Lu-dotatate extend neuroendocrine tumour PFS

Positive progression-free survival results from the RADIANT-4 and NETTER-1 trials extend the armamentarium for physicians treating patients with neuroendocrine tumours.

7 Oct 2015

IQWiG finds no added benefit for ceritinib drug in adults with NSCLC

The drug ceritinib (trade name: Zykadia) has been approved since May 2015 for the treatment of adults with non-small cell lung cancer (NSCLC). It is an option when certain changes in the cancer cells (anaplastic lymphoma kinase-positive) stimulate tumour growth and patients have already been pretreated with crizotinib.

7 Oct 2015

Lonza, Benitec partner to develop scalable manufacturing process for AAV-based viral gene therapies

Lonza Houston, Inc., a global leader in biological, cell and viral gene therapy manufacturing, and Benitec Biopharma, a clinical stage biotechnology company commercializing a patented gene-silencing technology, DNA-directed RNA interference (ddRNAi), today announced that they have entered into a Manufacturing Services Agreement to develop a scalable manufacturing process for Benitec's ddRNAi-based, Adeno-Associated Virus (AAV)-delivered products intended for therapeutic use in humans.

7 Oct 2015

Penn Medicine announces $375,000 in new grants to support BRCA-focused research projects

Penn Medicine's Basser Center for BRCA announced $375,000 in new grant funding to support BRCA-focused research projects across the nation. The grants are aimed at advancing the care of patients living with BRCA1 and BRCA2 mutations.

7 Oct 2015

Innovative service model leads to better results for patients with advanced cancer

An innovative service model that partners radiation oncology with palliative care leads to better results for patients, according to a new analysis. The model of care, established at Mount Sinai Medical Center in New York, is one of only a handful in the country. The study will be presented at the upcoming 2015 Palliative Care in Oncology Symposium in Boston.

7 Oct 2015

Researchers describe unknown mechanism behind progeria

Progeria, a premature aging disease, is the research focus of Roland Foisner's team at the Max F. Perutz Laboratories of the University of Vienna and the Medical University of Vienna. Children suffering from progeria die at an average age of 14 to 15 years, often from heart attacks and strokes.

7 Oct 2015

New capsule form of FMT raises hopes for treating C. difficile infection

A new capsule form of faecal microbiota transplantation (FMT) has raised hopes that this effective treatment for Clostridium difficile (C. difficile) infection and other bowel conditions might soon become mainstream. A recently-reported study confirmed that capsules containing a frozen suspension of faecal material harvested from healthy unrelated donors was well tolerated and effectively resolved diarrhoea in 90% of patients with difficult-to-treat C. difficile infection.

7 Oct 2015

Rabbit virus can be paired with existing drug to deliver more potent punch to brain tumor cells

A rabbit virus currently being developed for cancer therapy can be paired with one of several existing drugs to deliver a more potent punch to a deadly type of brain tumor cell, researchers have found.

7 Oct 2015

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx immunohistochemistry companion diagnostic.

From Quest Diagnostics 7 Oct 2015

OLFUS study supports safety, efficacy of DBV's Viaskin Peanut patch in children with peanut allergy

DBV Technologies, a clinical-stage specialty biopharmaceutical company, today announced that topline findings from the first 12 months of the OLFUS-VIPES study, or OLFUS, support the long-term safety and efficacy of Viaskin Peanut for the treatment of peanut allergy.

7 Oct 2015

Therapy News and Research

High levels of satiety hormone leptin contribute to cardiovascular disease in obese individuals

Head injury patients do not benefit from brain cooling therapy

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

Interim data from long-term extension Tecfidera® (dimethyl fumarate) study

Cell Therapy Catapult launches Cell History File

Texas Center for Proton Therapy lures top proton talent as Dallas center nears opening

2-year advanced melanoma survival benefit with dabrafenib, trametinib combination

Everolimus, 177Lu-dotatate extend neuroendocrine tumour PFS

IQWiG finds no added benefit for ceritinib drug in adults with NSCLC

Lonza, Benitec partner to develop scalable manufacturing process for AAV-based viral gene therapies

Penn Medicine announces $375,000 in new grants to support BRCA-focused research projects

Innovative service model leads to better results for patients with advanced cancer

Researchers describe unknown mechanism behind progeria

New capsule form of FMT raises hopes for treating C. difficile infection

Rabbit virus can be paired with existing drug to deliver more potent punch to brain tumor cells

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

OLFUS study supports safety, efficacy of DBV's Viaskin Peanut patch in children with peanut allergy

Binghamton University biochemist finds new way to fight cancer

Immune system protein has potential to prevent onset of aggressive form of rheumatoid arthritis

Researchers find link between El Niño and dengue epidemics

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News